報價延遲最少15分鐘:2025/01/11 11:16 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.75 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-21.00/-0.32
|
|
企業價值
27.80M
|
| 資產負債 |
|
每股賬面淨值
0.15
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
20.97M
|
|
每股收益
5.94
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/11 11:16 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features. |